http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 07:00:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html <p>BioXcel Therapeutics Inc. (NASDAQ: BTAI) presented new data from its Phase 3 SERENITY At-Home trial at the American Society of Clinical Psychopharmacology Annual Meeting in Miami. The trial evaluated BXCL501, a sublingual dexmedetomidine formulation, for treating agitation associated with bipolar disorders or schizophrenia in at-home settings.</p> <p>The presentation included exploratory efficacy analyses from the randomized, double-blind, placebo-controlled trial. Patients self-administered the study drug during agitation episodes over a 12-week period and assessed symptom severity using a modified Clinical Global Impression-Severity scale before dosing and two hours after.</p> <p>The analyses showed BXCL501 reduced agitation compared to placebo across all baseline symptom severity levels, http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html Thu, 28 May 2026 07:00:24 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html <p>BioXcel Therapeutics Inc. (NASDAQ: BTAI) presented new data from its Phase 3 SERENITY At-Home trial at the American Society of Clinical Psychopharmacology Annual Meeting in Miami. The trial evaluated BXCL501, a sublingual dexmedetomidine formulation, for treating agitation associated with bipolar disorders or schizophrenia in at-home settings.</p> <p>The presentation included exploratory efficacy analyses from the randomized, double-blind, placebo-controlled trial. Patients self-administered the study drug during agitation episodes over a 12-week period and assessed symptom severity using a modified Clinical Global Impression-Severity scale before dosing and two hours after.</p> <p>The analyses showed BXCL501 reduced agitation compared to placebo across all baseline symptom severity levels, http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html Thu, 28 May 2026 07:00:24 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html <p>BioXcel Therapeutics Inc. (NASDAQ: BTAI) presented new data from its Phase 3 SERENITY At-Home trial at the American Society of Clinical Psychopharmacology Annual Meeting in Miami. The trial evaluated BXCL501, a sublingual dexmedetomidine formulation, for treating agitation associated with bipolar disorders or schizophrenia in at-home settings.</p> <p>The presentation included exploratory efficacy analyses from the randomized, double-blind, placebo-controlled trial. Patients self-administered the study drug during agitation episodes over a 12-week period and assessed symptom severity using a modified Clinical Global Impression-Severity scale before dosing and two hours after.</p> <p>The analyses showed BXCL501 reduced agitation compared to placebo across all baseline symptom severity levels, http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html Thu, 28 May 2026 07:00:24 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html <p>BioXcel Therapeutics Inc. (NASDAQ: BTAI) presented new data from its Phase 3 SERENITY At-Home trial at the American Society of Clinical Psychopharmacology Annual Meeting in Miami. The trial evaluated BXCL501, a sublingual dexmedetomidine formulation, for treating agitation associated with bipolar disorders or schizophrenia in at-home settings.</p> <p>The presentation included exploratory efficacy analyses from the randomized, double-blind, placebo-controlled trial. Patients self-administered the study drug during agitation episodes over a 12-week period and assessed symptom severity using a modified Clinical Global Impression-Severity scale before dosing and two hours after.</p> <p>The analyses showed BXCL501 reduced agitation compared to placebo across all baseline symptom severity levels, http://www.streetinsider.com/FDA/BioXcel+presents+at-home+agitation+trial+data+at+medical+meeting/26560972.html Thu, 28 May 2026 07:00:24 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html <p>NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL.</p> <p>Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safety trial http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Presents+New+Data+from++SERENITY+At-Home+Phase+3+Trial+for+Agitation+Associated+with+Bipolar+Disorders+or+Schizophrenia+at+2026+ASCP+Annual+Meeting/26560924.html Thu, 28 May 2026 07:00:00 -0400 A.06822034 BTAI O.20026344 O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Yocca+Frank/26543252.html si-local-file:///var/storage/secattach/20260522/26543252.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Yocca+Frank/26543252.html Fri, 22 May 2026 19:03:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Yocca+Frank/26543252.html si-local-file:///var/storage/secattach/20260522/26543252.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Yocca+Frank/26543252.html Fri, 22 May 2026 19:03:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Steinhart+Richard+I/26543249.html si-local-file:///var/storage/secattach/20260522/26543249.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Steinhart+Richard+I/26543249.html Fri, 22 May 2026 19:02:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Steinhart+Richard+I/26543249.html si-local-file:///var/storage/secattach/20260522/26543249.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Steinhart+Richard+I/26543249.html Fri, 22 May 2026 19:02:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Rodriguez+Javier/26543250.html si-local-file:///var/storage/secattach/20260522/26543250.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Rodriguez+Javier/26543250.html Fri, 22 May 2026 19:02:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Rodriguez+Javier/26543250.html si-local-file:///var/storage/secattach/20260522/26543250.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Rodriguez+Javier/26543250.html Fri, 22 May 2026 19:02:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Mehta+Vimal/26543247.html si-local-file:///var/storage/secattach/20260522/26543247.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Mehta+Vimal/26543247.html Fri, 22 May 2026 19:00:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Mehta+Vimal/26543247.html si-local-file:///var/storage/secattach/20260522/26543247.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioXcel+Therapeutics%2C+++++For%3A+May+04++Filed+by%3A+Mehta+Vimal/26543247.html Fri, 22 May 2026 19:00:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Mehta+Vimal/26528807.html si-local-file:///var/storage/secattach/20260520/26528807.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Mehta+Vimal/26528807.html Wed, 20 May 2026 16:29:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Mehta+Vimal/26528807.html si-local-file:///var/storage/secattach/20260520/26528807.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Mehta+Vimal/26528807.html Wed, 20 May 2026 16:29:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Rodriguez+Javier/26528786.html si-local-file:///var/storage/secattach/20260520/26528786.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Rodriguez+Javier/26528786.html Wed, 20 May 2026 16:28:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Rodriguez+Javier/26528786.html si-local-file:///var/storage/secattach/20260520/26528786.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Rodriguez+Javier/26528786.html Wed, 20 May 2026 16:28:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Yocca+Frank/26528770.html si-local-file:///var/storage/secattach/20260520/26528770.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioXcel+Therapeutics%2C++++++++++++++++++Filed+by%3A+Yocca+Frank/26528770.html Wed, 20 May 2026 16:26:00 -0400 BTAI O.37678149